Cataract
Conditions
Keywords
Vivity, Cataract, Intraocular lens
Brief summary
The purpose of this research is to assess the rotational stability of the AcrySof IQ Vivity Extended Vision Toric IOL and Refractive Visual outcome.
Detailed description
Assessment of the rotational stability and Refractive Visual Outcome of the AcrySof IQ Vivity Extended Vision Toric IOL at the end of surgery, post op 1 day, post op 1 week and post op 4 weeks. Participants in this research study are 45 years of age or older and have planned implantation in at least one eye.
Interventions
DEVICEAlcon Vivity toric intra ocular lens
implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
Sponsors
Alcon Research
Eric Rosenberg, D.O.,M.Sc.Eng.
Kevin Barber
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Study will include adults (45 years and older) who plan to have cataract extraction and subsequent implantation of AcrySof® IQ Vivity™Extended Vision Toric IOL in at least one eye. Approximately 40 eye will be screened to identify 35 qualified eyes. Within 40 days of screening, qualified subjects will receive cataract surgery followed by implantation of the AcrySof® IQ Vivity™Extended Vision Toric IOL at the surgery visit. If the second eye will participate in the study, subjects will receive the second eye cataract surgery within 60 days of the Screening visit 0. Four postoperative follow up visits are planned to occur at 1-2 days, 7-14 days, and 28-35 days for each enrolled eye. Subject participation in this study is expected to last up to 2 months, including a total of 5 study visits for subjects implanted in one eye and up to 9 visits for subjects implanted in both eyes. Upon completion of the 35 day follow up visit subjects will be exited from the study.
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects undergoing cataract extraction with intraocular lens implantation. * Age: 45 years and older. * Willing and able to comply with scheduled visits and other study procedures. * Subjects who require an IOL power in the range of +15.0 D to +25.0 D. * Subjects with regular corneal astigmatism that can be treated with T3-T5. * Have good ocular health, with no pathology that compromises visual acuity (Outside of residual refractive error and cataract) * Potential postoperative visual acuity of 0.2 logMAR/ETDRS (20/32 Snellen) or better in both eyes.
Exclusion criteria
* Glaucoma. * Clinically significant corneal dystrophy. * Previous corneal refractive surgery (i.e LASIK, PRK, RK) * Pupil abnormalities. * Concurrent infectious/non-infectious uveitis. * History of chronic intraocular inflammation. * Visually significant macular disease. * History of retinal detachment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rotational stability of Vivity Toric IOL. | Five months | Rotational stability of Vivity Toric IOL will be measured at post op 1 day, post op 1 week and post op 4 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of eyes with residual refractive astigmatism, absolute residual astigmatism prediction error, and monocular distance and intermediate visual acuities. | Five months | Percentage of eyes with post op rotation of five degrees or less, absolute prediction of error ≤ 0.5 D, residual astigmatism ≤ 0.5 D, residual astigmatism 1.00 D. Monocular and Binocular UDVA, UIVA, UNVA, CDVA, DCIVA and DCNVA. |
Countries
United States
Outcome results
None listed